TY - JOUR
T1 - A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability (ESTIHIV)
AU - Raben, Dorthe
AU - Jakobsen, Marie L
AU - Trajanovska, Jamina
AU - Kowalska, Justyna
AU - Vassilenko, Anna
AU - Dragas, Snezana
AU - Harxhi, Arjan
AU - Dragovic, Gordana
AU - Jaschinski, Nadine J
AU - Neesgaard, Bastian
AU - Hjorth-Larsen, Klaus
AU - Garges, Harmony
AU - Gallant, Joel
AU - Lundgren, Jens D
AU - Philips, Andrew
AU - Cambiano, Valentina
AU - Yazdanpanah, Yazdan
AU - Mocroft, Amanda
N1 - Copyright: © 2025 Raben et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025
Y1 - 2025
N2 - Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring the HIV Continuum of Care to estimate efficacy of HIV treatment programmes. We developed an estimation-tool, ESTIHIV, and determined the minimal data required for a random sample, to produce representative estimates, with a specified level of precision, of people with HIV on ART and VS. For proof of concept, 8852 HIV positive persons from seven clinics in seven different countries, with a follow-up visit during 2017, were included. Of those, 93.8% were on ART (95% CI 93.3-94.2) and 76.7% were VS (95% CI 75.8-77.6). In 2022, we tested the tool in the RESPOND Cohort for all countries with more than 100 participants under follow-up in 2019. We included 26,426 HIV positive persons from clinics in 27 countries, 97.8% (95% CI 97.6-98.0) were on ART and 91.5% were VS (95% CI 91.2-91.8%). There was good agreement between the RESPOND country estimates of ART and VS and the estimations using a random sample calculated in ESTIHIV. With ESTIHIV, clinics can produce a reliable estimate in figures for reporting and for monitoring the effectiveness of care in their clinics.
AB - Many HIV clinics with poor IT-infrastructure are unable to report data on individuals in care with HIV, on antiretroviral treatment (ART) and virologically suppressed (VS), with the aim of monitoring the HIV Continuum of Care to estimate efficacy of HIV treatment programmes. We developed an estimation-tool, ESTIHIV, and determined the minimal data required for a random sample, to produce representative estimates, with a specified level of precision, of people with HIV on ART and VS. For proof of concept, 8852 HIV positive persons from seven clinics in seven different countries, with a follow-up visit during 2017, were included. Of those, 93.8% were on ART (95% CI 93.3-94.2) and 76.7% were VS (95% CI 75.8-77.6). In 2022, we tested the tool in the RESPOND Cohort for all countries with more than 100 participants under follow-up in 2019. We included 26,426 HIV positive persons from clinics in 27 countries, 97.8% (95% CI 97.6-98.0) were on ART and 91.5% were VS (95% CI 91.2-91.8%). There was good agreement between the RESPOND country estimates of ART and VS and the estimations using a random sample calculated in ESTIHIV. With ESTIHIV, clinics can produce a reliable estimate in figures for reporting and for monitoring the effectiveness of care in their clinics.
KW - Humans
KW - HIV Infections/drug therapy
KW - Female
KW - Male
KW - Anti-HIV Agents/therapeutic use
KW - Adult
KW - Continuity of Patient Care/statistics & numerical data
KW - Middle Aged
UR - http://www.scopus.com/inward/record.url?scp=85217357816&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0316794
DO - 10.1371/journal.pone.0316794
M3 - Journal article
C2 - 39879174
SN - 1932-6203
VL - 20
JO - PLoS One
JF - PLoS One
IS - 1
M1 - e0316794
ER -